Lundbeck

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release →

(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release →

(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release →

(PRESS RELEASE) VALBY, 4-Aug-2021 — /EuropaWire/ — Lundbeck (CPH: LUN), a Danish international pharmaceutical company, has announced it will partner with Rgenta Therapeutics, Cambridge, MA-based developer of oral, small-molecule RNA-targeting medicines with an initial focus on oncology, to discover small … Read the full press release →

(PRESS RELEASE) COPENHAGEN, 4-Feb-2021 — /EuropaWire/ — Danish international pharmaceutical company H. Lundbeck A/S (Lundbeck) announces its new 15-year climate target, which includes a detailed action plan to reduce emissions, approved by the Science Based Targets initiative (SBTi), towards becoming … Read the full press release →

(PRESS RELEASE) VALBY, Denmark, 22-Dec-2020 — /EuropaWire/ — Danish international pharmaceutical company, H. Lundbeck A/S (Lundbeck) announces that its marketing authorization application for Vyepti™ (eptinezumab-jjmr) has been accepted by the European Medicines Agency (EMA). The filing seeks approval to introduce … Read the full press release →

New treatment might have the potential to slow or stop the progression of Parkinson’s disease. VALBY, 12-Sep-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the … Read the full press release →

Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults. VALBY, 01-Aug-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Commission has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia … Read the full press release →

Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018. VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a … Read the full press release →

Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s … Read the full press release →

LONDON, 22-Dec-2016 — /EuropaWire/ — WPP announces that its wholly-owned operating company Grey Group, the global marketing communications company, has acquired Entreprise de Communications Tank Inc. (“Tank”), a leading full-service healthcare and consumer agency in Canada. Tank’s audited net revenues were … Read the full press release →

By implementing 40 different energy-saving and process optimization projects, and reducing its own emissions by 7% in 2015, Novozymes ranks among the top of CDP’s ‘A List’. Bagsvaerd, Denmark, 28-Oct-2016 — /EuropaWire/ — Against the backdrop of a historic Paris Agreement … Read the full press release →

Valby, Denmark and Osaka, Japan, 12-8-2015 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) announced today the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add … Read the full press release →

Turku, Finland, 25-7-2014 — /EuropaWire/ — Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with … Read the full press release →

Copenhagen, 16-7-2014 — /EuropaWire/ — Research from the University of Copenhagen is shedding new light on the brain’s complicated barrier tissue. The blood-brain barrier is an effective barrier which protects the brain, but which at the same time makes it difficult to … Read the full press release →

19-8-2013 — /EuropaWire/ — Company Highlights April – June 2013 Biotie obtained an exclusive option to acquire Neurelis, Inc., a private specialty pharmaceutical company based in San Diego, CA, focused on developing products for epilepsy and other disorders of the central nervous … Read the full press release →

Lundbeck aims to further improve its ability to launch new medicines through a new commercial structure. The initiative could lead to a reduction of around 50-55 positions in Europe. Valby, 21-6-2013 — /europawire.eu/ — H. Lundbeck A/S (Lundbeck) plans to further … Read the full press release →

Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines: statement by Vice-President Almunia Joaquín Almunia – Vice President of the European Commission responsible for Competition Policy Press conference, Brussels, 21-6-2013 — /europawire.eu/ — Today the European Commission has found … Read the full press release →

The European Commission has decided that Lundbeck’s agreements concluded with four generic competitors concerning citalopram violated competition law The decision includes fining Lundbeck EUR 93 million Lundbeck’s financial guidance for 2013 is maintained excluding costs connected to the fine Lundbeck is … Read the full press release →

Brussels, 20-6-2013 — /europawire.eu/ — The European Commission has imposed a fine of € 93,8 million on Danish pharmaceutical company Lundbeck and fines totalling € 52,2 million on several producers of generic medicines. In 2002, Lundbeck agreed with each of these … Read the full press release →